Biotech CAR-T roundup: Au­to­lus, Gra­cell tout ear­ly-stage da­ta at #ASH23

SAN DIEGO — Big Phar­ma com­pa­nies aren’t the on­ly play­ers at #ASH23. Many biotechs — in­clud­ing Au­to­lus and Gra­cell — who are look­ing to make their mark in hema­tol­ogy and blood can­cers are al­so here in Cal­i­for­nia to present CAR-T treat­ment da­ta.

Filed for ap­proval, Au­to­lus again ex­pands its dataset

Au­to­lus is work­ing on a CD19-di­rect­ed CAR-T called obe-cel to treat re­lapsed/re­frac­to­ry adult acute lym­phoblas­tic leukemia, go­ing for an in­di­ca­tion where Gilead’s Tecar­tus is al­ready ap­proved. Af­ter an­nounc­ing a topline win in De­cem­ber 2022 and flesh­ing out the da­ta at AS­CO ear­li­er this year, the UK biotech is back with an­oth­er up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER